-
-
In this Phase 2 trial, 105 older patients with acute myeloid leukemia who were either treatment-naïve or at first relapse were treated with one of three schedules of oral sapacitabine: 200 mg twice daily for 7 days (group A), 300 mg twice daily for 7 days (group B), or 400 mg twice daily for 3 days each week for 2 weeks (group C).
-
Denosumab is more effective than zoledronic acid at preventing pain in women with advanced breast cancer and bone metastases.
-
In a six-site Italian retrospective analysis, treatment of elderly patients with metastatic renal cell carcinoma with sunitinib was shown to be effective but associated with significant toxicity. Although only applied to a subset, pretreatment comprehensive geriatric assessment did not offer predictive value with regard to severe toxicity or efficacy.
-
Early pivotal trials demonstrating the efficacy of sorafenib for patients with advanced hepatocellular cancer included primarily those with minimal liver dysfunction (Child-Pugh [CP] class A).
-
LAP2 was a randomized, Phase 3 trial to evaluate and compare the modality of surgical staging (laparoscopy vs laparotomy) in endometrial cancer.
-
This Phase 1 clinical trial evaluated the safety and pharmacokinetics of intraventricular immune-chemotherapy with twice weekly rituximab (10 mg and 25 mg) and methotrexate in 14 patients with recurrent central nervous system lymphoma (primary or secondary).
-
Aspirin use and AMD risk; using NSAIDs and antihypertensive agents; and FDA actions.
-
-
In a randomized, Phase 2 trial, weekly maintenance cetuximab for 12 weeks after concomitant definitive radiation therapy/cetuximab induction was associated with better disease-free survival at 1 year.
